Tumor Biology

, Volume 35, Issue 10, pp 10333–10340 | Cite as

Clinicopathological significance of RUNX3 gene hypermethylation in hepatocellular carcinoma

  • Yuewu Yang
  • Zhiqiang Ye
  • Zengcheng Zou
  • Gemin Xiao
  • Gangjian Luo
  • Hongzhi Yang
Research Article


Emerging evidence indicates that RUNX3 is a candidate tumor suppressor in several types of human tumors including hepatocellular carcinoma (HCC). However, the correlation between RUNX3 hypermethylation and incidence of HCC remains unclear. Here, we conducted a systematic review and meta-analysis aiming to comprehensively assess the potential role of RUNX3 hypermethylation in the pathogenesis of HCC. A detailed literature search was made from PubMed, EMBASE, and ISI web of knowledge to identify studies for related research publications. Methodological quality of the studies was also evaluated. The data were extracted and assessed by two reviewers independently. Analysis of pooled data was performed. Odds ratio (OR) was calculated and summarized, respectively. Final analysis of 821 HCC patients from 14 eligible studies was performed. We observed that RUNX3 hypermethylation was significantly higher in HCC than in normal liver tissue, the pooled OR from eight studies including 382 HCC and 161 normal liver tissue (OR = 39.32, 95 % confidence interval (CI) = 13.72–112.7, p < 0.00001). The pooled analysis showed significantly increased OR of RUNX3 hypermethylation (OR = 5.4, 95 % CI = 2.06–14.17, p < 0.00001) in HCC tissues and non-tumor liver tissues. In addition, statistically significant OR of RUNX3 hypermethylation was obtained from non-tumorous liver tissue of HCC patients and normal liver tissue (OR = 12.57, 95 % CI = 3.56–44.35, p < 0.0001). The results of this meta-analysis suggest that RUNX3 hypermethylation may be implicated in the pathogenesis of HCC. Thus, detection of RUNX3 hypermethylation may be a helpful and valuable biomarker for diagnosis of HCC.


RUNX3 Methylation Hepatocellular carcinoma Tumor suppressor gene Meta-analysis Odds ratio 


Conflicts of interest



  1. 1.
    Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.CrossRefPubMedGoogle Scholar
  2. 2.
    Singal AG, Pillai A, Tiro J. Early detection, curative treatment, and survival rates for hepatocellular carcinoma surveillance in patients with cirrhosis: a meta-analysis. PLoS Med. 2014;11:e1001624.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Graf D, Vallbohmer D, Knoefel WT, et al. Multimodal treatment of hepatocellular carcinoma. Eur J Intern Med. 2014;22:00076–4.Google Scholar
  4. 4.
    Ozaki T, Nakagawara A, Nagase H. RUNX family participates in the regulation of p53-dependent DNA damage response. Int J Genom. 2013;2013:271347.Google Scholar
  5. 5.
    Ito Y. RUNX genes in development and cancer: regulation of viral gene expression and the discovery of RUNX family genes. Adv Cancer Res. 2008;99:33–76.CrossRefPubMedGoogle Scholar
  6. 6.
    Blyth K, Cameron ER, Neil JC. The RUNX genes: gain or loss of function in cancer. Nat Rev Cancer. 2005;5:376–87.CrossRefPubMedGoogle Scholar
  7. 7.
    Subramaniam MM, Chan JY, Yeoh KG, Quek T, Ito K, Salto-Tellez M. Molecular pathology of RUNX3 in human carcinogenesis. Biochim Biophys Acta. 2009;1796:315–31.PubMedGoogle Scholar
  8. 8.
    Lund AH, van Lohuizen M. RUNX: a trilogy of cancer genes. Cancer Cell. 2002;1:213–5.CrossRefPubMedGoogle Scholar
  9. 9.
    Levanon D, Negreanu V, Bernstein Y, Bar-Am I, Avivi L, Groner Y. AML1, AML2, and AML3, the human members of the runt domain gene-family: cDNA structure, expression, and chromosomal localization. Genomics. 1994;23:425–32.CrossRefPubMedGoogle Scholar
  10. 10.
    Chi XZ, Kim J, Lee YH, et al. Runt-related transcription factor RUNX3 is a target of MDM2-mediated ubiquitination. Cancer Res. 2009;69:8111–9.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Shiraha H, Nishina S, Yamamoto K. Loss of runt-related transcription factor 3 causes development and progression of hepatocellular carcinoma. J Cell Biochem. 2011;112:745–9.CrossRefPubMedGoogle Scholar
  12. 12.
    Li QL, Ito K, Sakakura C, et al. Causal relationship between the loss of RUNX3 expression and gastric cancer. Cell. 2002;109:113–24.CrossRefPubMedGoogle Scholar
  13. 13.
    Chi XZ, Yang JO, Lee KY, et al. RUNX3 suppresses gastric epithelial cell growth by inducing p21(WAF1/Cip1) expression in cooperation with transforming growth factor {beta}-activated SMAD. Mol Cell Biol. 2005;25:8097–107.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Wei D, Gong W, Oh SC, et al. Loss of RUNX3 expression significantly affects the clinical outcome of gastric cancer patients and its restoration causes drastic suppression of tumor growth and metastasis. Cancer Res. 2005;65:4809–16.CrossRefPubMedGoogle Scholar
  15. 15.
    Chen LF. Tumor suppressor function of RUNX3 in breast cancer. J Cell Biochem. 2012;113:1470–7.PubMedPubMedCentralGoogle Scholar
  16. 16.
    Tanaka S, Shiraha H, Nakanishi Y, et al. Runt-related transcription factor 3 reverses epithelial-mesenchymal transition in hepatocellular carcinoma. Int J Cancer. 2012;131:2537–46.CrossRefPubMedGoogle Scholar
  17. 17.
    Li J, Jiang X. Loss of runt-related transcription factor 3 expression associated with human hepatocellular carcinoma progression and prognosis. Asian Pac J Cancer Prev. 2011;12:2285–90.PubMedGoogle Scholar
  18. 18.
    McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM. Reporting recommendations for tumor marker prognostic studies (REMARK). J Natl Cancer Inst. 2005;97:1180–4.CrossRefPubMedGoogle Scholar
  19. 19.
    Steels E, Paesmans M, Berghmans T, et al. Role of p53 as a prognostic factor for survival in lung cancer: a systematic review of the literature with a meta-analysis. Eur Respir J. 2001;18:705–19.CrossRefPubMedGoogle Scholar
  20. 20.
    DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177–88.CrossRefPubMedGoogle Scholar
  21. 21.
    Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557–60.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    DerSimonian R. Meta-analysis in the design and monitoring of clinical trials. Stat Med. 1996;15:1237–48. discussion 49–52.CrossRefPubMedGoogle Scholar
  23. 23.
    Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629–34.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Li J, Jiang X. Methylation of RUNX3 gene promoter in HCC and its significance. J Third Mil Med Univ. 2012;34(19):1433–5.Google Scholar
  25. 25.
    Xiao WH, Liu WW. Hemizygous deletion and hypermethylation of RUNX3 gene in hepatocellular carcinoma. World J Gastroenterol. 2004;10:376–80.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Kim TY, Lee HJ, Hwang KS, et al. Methylation of RUNX3 in various types of human cancers and premalignant stages of gastric carcinoma. Lab Invest. 2004;84:479–84.CrossRefPubMedGoogle Scholar
  27. 27.
    Park WS, Cho YG, Kim CJ, et al. Hypermethylation of the RUNX3 gene in hepatocellular carcinoma. Exp Mol Med. 2005;37:276–81.CrossRefPubMedGoogle Scholar
  28. 28.
    Nomoto S, Kinoshita T, Kato K, et al. Hypermethylation of multiple genes as clonal markers in multicentric hepatocellular carcinoma. Br J Cancer. 2007;97:1260–5.CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Nishida N, Nagasaka T, Nishimura T, Ikai I, Boland CR, Goel A. Aberrant methylation of multiple tumor suppressor genes in aging liver, chronic hepatitis, and hepatocellular carcinoma. Hepatology. 2008;47:908–18.CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Moribe T, Iizuka N, Miura T, et al. Methylation of multiple genes as molecular markers for diagnosis of a small, well-differentiated hepatocellular carcinoma. Int J Cancer. 2009;125:388–97.CrossRefPubMedGoogle Scholar
  31. 31.
    Miyagawa K, Sakakura C, Nakashima S, et al. Down-regulation of RUNX1, RUNX3 and CBFbeta in hepatocellular carcinomas in an early stage of hepatocarcinogenesis. Anticancer Res. 2006;26:3633–43.PubMedGoogle Scholar
  32. 32.
    Hua D, Hu Y, Wu YY, et al. Quantitative methylation analysis of multiple genes using methylation-sensitive restriction enzyme-based quantitative PCR for the detection of hepatocellular carcinoma. Exp Mol Pathol. 2011;91:455–60.CrossRefPubMedGoogle Scholar
  33. 33.
    Feng Q, Stern JE, Hawes SE, Lu H, Jiang M, Kiviat NB. DNA methylation changes in normal liver tissues and hepatocellular carcinoma with different viral infection. Exp Mol Pathol. 2010;88:287–92.CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Lee HS, Kim BH, Cho NY, et al. Prognostic implications of and relationship between CpG island hypermethylation and repetitive DNA hypomethylation in hepatocellular carcinoma. Clin Cancer Res. 2009;15:812–20.CrossRefPubMedGoogle Scholar
  35. 35.
    Tan SH, Ida H, Lau QC, et al. Detection of promoter hypermethylation in serum samples of cancer patients by methylation-specific polymerase chain reaction for tumour suppressor genes including RUNX3. Oncol Rep. 2007;18:1225–30.PubMedGoogle Scholar
  36. 36.
    Nishida N, Kudo M, Nagasaka T, Ikai I, Goel A. Characteristic patterns of altered DNA methylation predict emergence of human hepatocellular carcinoma. Hepatology. 2012;56:994–1003.CrossRefPubMedGoogle Scholar
  37. 37.
    Jiang X, Li G, Lin Z. Hypermethylation of the RUNX3 gene promoter and mRNA expression in hepatocellular carcinoma and significance. Chin J Exp Surg. 2011;10:1640–2.Google Scholar
  38. 38.
    Chuang LS, Ito Y. RUNX3 is multifunctional in carcinogenesis of multiple solid tumors. Oncogene. 2010;29:2605–15.CrossRefPubMedGoogle Scholar
  39. 39.
    Lee JH, Pyon JK, Kim DW, et al. Expression of RUNX3 in skin cancers. Clin Exp Dermatol. 2011;36:769–74.CrossRefPubMedGoogle Scholar
  40. 40.
    Lee JM, Shin JO, Cho KW, et al. Runx3 is a crucial regulator of alveolar differentiation and lung tumorigenesis in mice. Differentiation. 2011;81:261–8.CrossRefPubMedGoogle Scholar
  41. 41.
    Lee YM. Control of RUNX3 by histone methyltransferases. J Cell Biochem. 2011;112:394–400.CrossRefPubMedGoogle Scholar
  42. 42.
    Levanon D, Brenner O, Otto F, Groner Y. Runx3 knockouts and stomach cancer. EMBO Rep. 2003;4:560–4.CrossRefPubMedPubMedCentralGoogle Scholar
  43. 43.
    Lee YS, Lee JW, Jang JW, et al. Runx3 inactivation is a crucial early event in the development of lung adenocarcinoma. Cancer Cell. 2013;24:603–16.CrossRefPubMedGoogle Scholar
  44. 44.
    Araki K, Osaki M, Nagahama Y, et al. Expression of RUNX3 protein in human lung adenocarcinoma: implications for tumor progression and prognosis. Cancer Sci. 2005;96:227–31.CrossRefPubMedGoogle Scholar
  45. 45.
    Delpu Y, Cordelier P, Cho WC, Torrisani J. DNA methylation and cancer diagnosis. Int J Mol Sci. 2013;14:15029–58.CrossRefPubMedPubMedCentralGoogle Scholar
  46. 46.
    Ma X, Wang YW, Zhang MQ, Gazdar AF. DNA methylation data analysis and its application to cancer research. Epigenomics. 2013;5:301–16.CrossRefPubMedPubMedCentralGoogle Scholar
  47. 47.
    Voon DC, Wang H, Koo JK, et al. Runx3 protects gastric epithelial cells against epithelial-mesenchymal transition-induced cellular plasticity and tumorigenicity. Stem Cells. 2012;30:2088–99.CrossRefPubMedGoogle Scholar
  48. 48.
    Lee SH, Bae SC, Kim KW, Lee YM. RUNX3 inhibits hypoxia-inducible factor-1alpha protein stability by interacting with prolyl hydroxylases in gastric cancer cells. Oncogene. 2014;33(11):1458–67.CrossRefPubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2014

Authors and Affiliations

  • Yuewu Yang
    • 1
  • Zhiqiang Ye
    • 2
  • Zengcheng Zou
    • 1
  • Gemin Xiao
    • 1
  • Gangjian Luo
    • 3
  • Hongzhi Yang
    • 1
  1. 1.Department of Traditional Chinese MedicineThird Affiliated Hospital of Sun Yat-sen UniversityGuangzhouChina
  2. 2.Department of EmergencyThird Affiliated Hospital of Sun Yat-sen UniversityGuangzhouChina
  3. 3.Department of AnesthesiologyThird Affiliated Hospital of Sun Yat-sen UniversityGuangzhouChina

Personalised recommendations